Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes

Analytical and Bioanalytical Chemistry

Volumn 408, Issue 19, 2016, Pages 5277-5284

  Vinhas, Raquel ^a   Correia, Cláudia ^a   Ribeiro, Patricia ^b   Lourenço, Alexandra ^b   Botelho de Sousa, Aida ^b   Fernandes, Alexandra R ^a   Baptista, Pedro V ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b HOSPITAL DOS CAPUCHOS   (Portugal)

Author keywords

Chronic myeloid leukemia; Colorimetric detection; Gold nanoparticles; Leukemia; RNA

Indexed keywords

CHAINS; COLOR; COLORIMETRY; DIAGNOSIS; DISEASES; DNA; DNA SEQUENCES; FIBER OPTIC SENSORS; GOLD; METAL NANOPARTICLES; NANOPARTICLES; NANOPROBES; NUCLEIC ACIDS; OLIGONUCLEOTIDES; OPTICAL PROPERTIES; RNA; TRANSCRIPTION;

CHRONIC MYELOID LEUKEMIAS; COLORIMETRIC DETECTION; COLORIMETRIC METHODS; GOLD NANOPARTICLES; LEUKEMIA; NESTED POLYMERASE CHAIN REACTION; QUANTITATIVE POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION;

POLYMERASE CHAIN REACTION;

BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; GOLD; METAL NANOPARTICLE; RNA; TRANSCRIPTION FACTOR;

CHEMISTRY; COLORIMETRY; GENETIC PROCEDURES; GENETICS; HUMAN; MOLECULAR PROBE; MYELOID LEUKEMIA; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TUMOR CELL CULTURE;

COLORIMETRY; FUSION PROTEINS, BCR-ABL; GOLD; HUMANS; LEUKEMIA, MYELOID; METAL NANOPARTICLES; MOLECULAR PROBE TECHNIQUES; MOLECULAR PROBES; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84969988700     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-016-9622-9     Document Type: Article

References (33)

1. Larguinho M, Canto R, Cordeiro M, Pedrosa P, Fortuna A, Vinhas R, et al. Gold nanoprobe-based non-crosslinking hybridization for molecular diagnostics. Expert Rev Mol Diagn. 2015;15(10):1355–68.
2. Doria G, Conde J, Veigas B, Giestas L, Almeida C, Assunção M, et al. Noble metal nanoparticles for biosensing applications. Sensors. 2012;12(2):1657–87.
3. Conde J, de la Fuente JM, Baptista PV. RNA quantification using gold nanoprobes—application to cancer diagnostics. J Nanobiotechnol. 2010;8:5.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
5. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547–56.
6. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342–50.
7. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood. 2010;116(19):3758–65.
8. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011;118(6):1622–31.
9. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res. 2011;17(21):6812–21.
10. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et al. Tolerability adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29(12):1634–42.
11. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukemia. Nature. 1973;243:290–3.
12. Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007;92(12):1699–702.
13. Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia—retrospective study and review of literature. Leuk Res. 2004;28(6):579–86.
14. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 1985;315:550–4.
15. Weerkamp F, Dekking E, Ng YY, Van der Velden VHJ, Wai H, Böttcher S, et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia. 2009;23(6):1106–17.
16. Heisterkamp N, Groffen J. Philadelphia-positive leukemia: a personal perspective. Oncogene. 2002;21(56):8536–40.
17. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21(56):8652–67.
18. Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia—a possible influence of mdr1 gene expression. Hematol Rep. 2011;3(1), e3.
19. Kantarjian H, O’Brien S, Cortes J, Giles F, Thomas D, Kornblau S, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81–5.
20. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189(9):1399–412.
21. Ou J, Vergilio JA, Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol. 2008;83(4):296–302.
22. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107(3):587–99.
23. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.
24. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330–8.
25. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
26. Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(2):S141–7.
27. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901–28.
28. Drexler HG. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leuk Res. 2000;24(2):109–15.
29. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186–93.
30. CanTreat International. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic? Ann Oncol. 2010;21(4):680–2.
31. Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol. 2013;34(3):154.
32. Tekinturhan E, Audureau E, Tavolacci MP, Garcia-Gonzalez P, Ladner J, Saba J. Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program. BMC Health Serv Res. 2013;13(1):304.
33. Garcia-Gonzalez P, Boultbee P, Epstein D 2015 Novel humanitarian aid program: the Glivec International Patient Assistance Program—lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries. J Glob Oncol 000570